Generalized myasthenia gravis (gMG)
A 9-month study of an investigational oral, once-daily treatment that blocks a specific immune-system protein linked to gMG muscle weakness. It is compared with a placebo over a 6-month treatment phase, followed by follow-up visits.
You may be eligible if you
- Are between 18 and 85 years old
- Have a confirmed gMG diagnosis with positive AChR antibodies
- Have significant non-ocular symptoms, such as muscle weakness or fatigue
- Have been on a stable gMG treatment for at least 6 months (for example NSISTs, IVIG/PLEX, FcRn antagonists or rituximab)
Study timeline
Visit spacing is illustrative. Your coordinator gives you the exact schedule. A recent thymectomy (within 6 months), some recent treatments or an active infection may pause eligibility.


